/
APRE
$0.82+$0.03 (+3.67%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$9.8M
12M shares
52-week range
$0.55 – $2.22
16% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
10.56%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-107.58
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $583.2K | $1.5M | $0 |
| Cost of revenue | $8.3K | $170.3K | $229.6K | $271.7K | $16.4M | $7.1K | $9.4M | $0 |
| Gross profit | −$8.3K | −$170.3K | −$229.6K | −$271.7K | −$16.4M | $576.2K | −$7.9M | $0 |
| Gross margin | — | — | — | — | — | 98.8% | -523.2% | — |
| R&D | $14.2M | $21.0M | $37.9M | $23.9M | $92.4M | $7.6M | $9.4M | $7.0M |
| Operating income | −$16.5M | −$29.5M | −$52.8M | −$37.4M | −$113.4M | −$15.5M | −$14.3M | −$13.2M |
| EBITDA | −$15.5M | −$27.9M | −$53.2M | −$36.9M | −$37.4M | −$14.3M | −$12.9M | −$12.6M |
| Net income | −$15.5M | −$28.1M | −$53.9M | −$36.5M | −$112.7M | −$14.3M | −$13.0M | −$12.6M |
| Net margin | — | — | — | — | — | -2449.6% | -862.4% | — |
| EPS (diluted) | -22.06 | -26.28 | -50.61 | -34.88 | -1359.79 | -3.95 | -2.35 | -1.93 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $1M | $-0.69 | $-0.78–$-0.54 | 3 |
| 2027 | $2M | $-0.66 | $-0.88–$-0.35 | 3 |
| 2028 | $4M | $-0.73 | $-1.17–$-0.42 | 4 |
| 2029 | $12M | $-0.47 | $-0.47–$-0.47 | 2 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$2.13
Price
$0.82
Implied upside
+161%
Peer comparison
Aprea Therapeutics, Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.
www.aprea.com- Employees
- 8
- IPO / List date
- Oct 3, 2019
- HQ
- DOYLESTOWN, PA
Held by traders on TradeandTell
No one on the platform currently holds APRE.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 25,100 | $19.1K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2023-02-13 | 1-for-20reverse |
| 2018-12-27 | 1-for-1000reverse |
| 2011-09-13 | 1-for-500reverse |
Recent trades on TradeandTell
No one on the platform has traded APRE yet.
